低剂量司美格鲁肽：既能显著减重，又能减少副作用

Core Insights - The article discusses the effectiveness of personalized dosing of semaglutide in preventing weight regain during weight loss programs, emphasizing the importance of lifestyle guidance alongside medication [4][6]. Group 1: Research Findings - A recent study presented at the European Obesity Congress (ECO) highlights the advantages of using personalized doses of semaglutide in weight loss plans [4]. - The study involved 2,246 individuals in Denmark, primarily women with an average age of 49 and an average BMI of 33.2, participating in a weight management program that included dietary advice, exercise, and psychological support [9]. - The average weight loss reported at week 64 was 14.8% (approximately 14.8 kg), and at week 76, it was 14.9% (approximately 14.9 kg) [12]. Group 2: Medication and Dosing - Semaglutide, a GLP-1 receptor agonist, mimics the action of the GLP-1 hormone to reduce appetite and increase satiety [5]. - The standard dosing protocol involves starting with a lower dose (0.25 mg weekly) and gradually increasing it, with a maximum dose of 2 mg for Ozempic and 2.4 mg for Wegovy [11]. - Patients in the study used approximately one-third of the standard treatment dose, with an average maximum dose of 0.77 mg [12]. Group 3: Patient Outcomes - All 68 patients who reported their weight at week 64 experienced a weight loss of over 5%, with 85.3% of them losing more than 10% of their baseline weight [13]. - The study suggests that combining medication with nutritional and exercise guidance can significantly reduce the likelihood of weight regain after stopping the medication [6].